© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
R Scott Turner, PhD, MD
Articles
Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD
January 28, 2025
Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.
Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD
January 27, 2025
Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.
Anti-Amyloid Antibodies in Short: R Scott Turner, PhD, MD Explains
January 24, 2025
The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.